352 related articles for article (PubMed ID: 27754444)
1. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
Zhu X; Bian H; Gao X
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754444
[TBL] [Abstract][Full Text] [Related]
2. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
3. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
4. Berberine prevents NAFLD and HCC by modulating metabolic disorders.
Lin X; Zhang J; Chu Y; Nie Q; Zhang J
Pharmacol Ther; 2024 Feb; 254():108593. PubMed ID: 38301771
[TBL] [Abstract][Full Text] [Related]
5. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.
Guo T; Woo SL; Guo X; Li H; Zheng J; Botchlett R; Liu M; Pei Y; Xu H; Cai Y; Zeng T; Chen L; Li X; Li Q; Xiao X; Huo Y; Wu C
Sci Rep; 2016 Mar; 6():22612. PubMed ID: 26936230
[TBL] [Abstract][Full Text] [Related]
6. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
Wang Y; Tai YL; Zhao D; Zhang Y; Yan J; Kakiyama G; Wang X; Gurley EC; Liu J; Liu J; Liu J; Lai G; Hylemon PB; Pandak WM; Chen W; Zhou H
Cells; 2021 Jan; 10(2):. PubMed ID: 33494295
[TBL] [Abstract][Full Text] [Related]
7. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
8. Berberine in Non-Alcoholic Fatty Liver Disease-A Review.
Koperska A; Wesołek A; Moszak M; Szulińska M
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079717
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Yan HM; Xia MF; Wang Y; Chang XX; Yao XZ; Rao SX; Zeng MS; Tu YF; Feng R; Jia WP; Liu J; Deng W; Jiang JD; Gao X
PLoS One; 2015; 10(8):e0134172. PubMed ID: 26252777
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats.
Li QP; Dou YX; Huang ZW; Chen HB; Li YC; Chen JN; Liu YH; Huang XQ; Zeng HF; Yang XB; Su ZR; Xie JH
Phytomedicine; 2021 May; 85():153550. PubMed ID: 33831691
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling.
Zhao J; Wang Y; Wu X; Tong P; Yue Y; Gao S; Huang D; Huang J
Mol Med Rep; 2018 Nov; 18(5):4635-4642. PubMed ID: 30221732
[TBL] [Abstract][Full Text] [Related]
12. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.
Yuan X; Wang J; Tang X; Li Y; Xia P; Gao X
J Transl Med; 2015 Jan; 13():24. PubMed ID: 25623289
[TBL] [Abstract][Full Text] [Related]
13. Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products.
Xu G; Huang K; Zhou J
Curr Med Chem; 2018; 25(8):889-907. PubMed ID: 28393690
[TBL] [Abstract][Full Text] [Related]
14. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Xing LJ; Zhang L; Liu T; Hua YQ; Zheng PY; Ji G
Eur J Pharmacol; 2011 Oct; 668(3):467-71. PubMed ID: 21839075
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway.
Lu Z; He B; Chen Z; Yan M; Wu L
BMC Immunol; 2020 May; 21(1):28. PubMed ID: 32429849
[TBL] [Abstract][Full Text] [Related]
16. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Ionita-Radu F; Patoni C; Nancoff AS; Marin FS; Gaman L; Bucurica A; Socol C; Jinga M; Dutu M; Bucurica S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673787
[TBL] [Abstract][Full Text] [Related]
17. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase.
Li J; Pan Y; Kan M; Xiao X; Wang Y; Guan F; Zhang X; Chen L
Life Sci; 2014 Mar; 98(1):24-30. PubMed ID: 24412384
[TBL] [Abstract][Full Text] [Related]
18. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin.
Feng WW; Kuang SY; Tu C; Ma ZJ; Pang JY; Wang YH; Zang QC; Liu TS; Zhao YL; Xiao XH; Wang JB
Biomed Pharmacother; 2018 Mar; 99():325-333. PubMed ID: 29353208
[TBL] [Abstract][Full Text] [Related]
19. Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase.
Chang W; Zhang M; Li J; Meng Z; Wei S; Du H; Chen L; Hatch GM
Metabolism; 2013 Aug; 62(8):1159-67. PubMed ID: 23537779
[TBL] [Abstract][Full Text] [Related]
20. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
